Regulation of Dihydroartemisinin on the pathological progression of laryngeal carcinoma through the periostin/YAP/IL-6 pathway

Xin-yu Zhang; Rui-cong Li; Cong Xu; Xiao-ming Li

Heliyon (Mar 2024)

Regulation of Dihydroartemisinin on the pathological progression of laryngeal carcinoma through the periostin/YAP/IL-6 pathway

Xin-yu Zhang,
Rui-cong Li,
Cong Xu,
Xiao-ming Li

Affiliations

Xin-yu Zhang: Graduate School of Hebei Medical University, 050000, Shijiazhuang, China; Department of Otolaryngology, Head and Neck Surgery, NO.980 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, 050000, Shijiazhuang, China; Department of Otolaryngology, Baoding No.1 Central Hospital, 071000, Baoding, China
Rui-cong Li: Department of Otolaryngology, Head and Neck Surgery, The Fourth Hospital of Hebei Medical University, 050000, Shijiazhuang, China
Cong Xu: Department of Otolaryngology, Head and Neck Surgery, NO.980 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, 050000, Shijiazhuang, China
Xiao-ming Li: Department of Otolaryngology, Head and Neck Surgery, NO.980 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, 050000, Shijiazhuang, China; Corresponding author.

Journal volume & issue: Vol. 10, no. 6
p. e27494

Abstract

Read online

Objective: Laryngeal cancer (LC) is one of the most common squamous cell carcinomas of the head and neck in clinical practice, and its incidence has been increasing in recent years, but the prognosis of the patients is not favorable. Hence, it is critical to re-understand and deeply study the causes and mechanisms of LC and explore new effective treatment methods and strategies. In this study, we analyzed the effect of Dihydroartemisinin (DHA) on the pathological progression of LC through the periostin (POSTN)/Yes-associated protein (YAP)/interleukin (IL)-6 pathway, which can provide new clinical references and guidelines. Methods: POSTN, YAP, and IL-6 levels in 18 pairs of fresh LC tissues and adjacent counterparts in our hospital were detected. Additionally, LC TU686 cell line was purchased for DHA treatment of various concentrations to detect changes in cell biological behavior. Finally, we built a tumor-bearing mouse model with C57BL/6 mice and intragastrically administrated DHA to the animals to observe the growth of living tumors and to measure POSTN, YAP, and IL-6 expression in tumor tissues. Results: As indicated by PCR, Western blotting, and immunohistochemistry, POSTN, YAP, and IL-6 presented higher expression in LC tissues than in adjacent counterparts. In cell experiments, the cloning rate of LC cells decreased and the apoptosis rate increased after DHA intervention, with 160 μmol/L DHA contributing to the most significant effect on LC activity inhibition. Furthermore, DHA-intervened cells exhibited markedly reduced POSTN, YAP, and IL-6 levels. Finally, the tumorigenesis experiment in nude mice showed inhibited tumor growth after DHA administration. And consistently, the expressions of POSTN, YAP, and IL-6 in living tumors decreased. Conclusions: DHA can inhibit POSTN/YAP/IL-6 transduction, accelerate LC cell apoptosis, and alleviate the malignant progression of LC.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords